Nearly all antipsychotics carry some risk of QT prolongation, but the degree varies widely. Thioridazine and ziprasidone sit at the top of the risk list, while lurasidone and aripiprazole carry the least cardiac concern. The difference between a high-risk and low-risk antipsychotic can be 20 or more milliseconds of QTc change, which matters because crossing the 500-millisecond threshold sharply increases the chance of a dangerous heart rhythm.
How Antipsychotics Affect Heart Rhythm
Your heart’s electrical cycle depends on ions flowing in and out of cells through tiny channels. Antipsychotics can block a specific potassium channel (called the hERG channel) that’s responsible for resetting the heart’s electrical charge after each beat. When that channel is blocked, the heart takes longer to reset, stretching out the QT interval on an ECG. A moderately prolonged QT interval often causes no symptoms, but extreme prolongation can trigger a chaotic heart rhythm called torsades de pointes, which can cause fainting, cardiac arrest, or sudden death.
Drug-induced torsades de pointes is rare, occurring in roughly 15 cases per 10,000 patient-years of exposure. But because the consequences can be fatal, knowing which medications carry the highest risk is genuinely useful.
High-Risk Antipsychotics
Thioridazine consistently ranks as the antipsychotic with the greatest effect on QTc. In controlled studies, it increased the QTc interval from a baseline of about 401 milliseconds to 429 milliseconds, a jump of nearly 30 ms. That finding led the FDA to add a black-box warning, and thioridazine is now rarely prescribed as a first-line treatment.
Sertindole falls into the same tier. Nearly 8% of patients taking sertindole developed QTc prolongation beyond 500 ms in clinical data, which was enough for the FDA to block its approval in the United States entirely.
Ziprasidone is the highest-risk option among the commonly used newer antipsychotics. In a large real-world cohort study, ziprasidone carried a hazard ratio of 1.72 for QTc prolongation compared to baseline. Meta-analyses of clinical trials found that ziprasidone, along with sertindole and amisulpride, prolonged QTc by more than 20 ms compared to placebo.
Moderate-Risk Antipsychotics
Amisulpride showed a hazard ratio of 1.56 for QTc prolongation in real-world data. Olanzapine was close behind at 1.40. Both reached statistical significance, meaning the association was unlikely to be a fluke, but neither approached the risk level of ziprasidone or thioridazine.
Meta-analyses place quetiapine, risperidone, and olanzapine in a band that marginally prolongs QTc by 5 to 15 ms. For most healthy people, that range is clinically insignificant on its own. It becomes more relevant when other risk factors pile up, such as older age, electrolyte problems, or additional medications that also stretch the QT interval.
When comparing older (first-generation) antipsychotics, the general ranking from most to least QTc effect runs: thioridazine, then haloperidol at the lower end. Haloperidol deserves a special note: oral doses carry a relatively modest QTc risk, but intravenous haloperidol has been linked to torsades de pointes in case reports, likely because IV delivery produces higher peak blood levels.
Lower-Risk Antipsychotics
Several newer antipsychotics show minimal or no meaningful QTc effect. Lurasidone consistently comes out as the antipsychotic least associated with QT prolongation across both clinical trials and post-marketing safety reports. Aripiprazole and brexpiprazole, which work as partial dopamine agonists rather than full blockers, also rank among the safest options for cardiac rhythm.
In the large retrospective cohort study from BJPsych Open, risperidone, clozapine, quetiapine, paliperidone, and aripiprazole showed no statistically significant association with QTc prolongation after adjustment. That doesn’t mean they carry zero risk, but it does place them in a clearly lower tier than ziprasidone or amisulpride.
Risk Factors That Compound the Problem
The antipsychotic itself is often just one piece of the puzzle. Most published cases of torsades de pointes in patients taking antipsychotics involved at least one or two additional risk factors. The major ones are:
- Female sex. Women naturally have slightly longer QTc intervals and are more susceptible to drug-induced prolongation.
- Older age. Elderly patients face higher risk due to age-related changes in heart conduction and kidney function, which slows drug clearance.
- Low potassium or magnesium. These electrolyte imbalances directly impair the same ion channels that antipsychotics block, amplifying the effect.
- Heart disease. Pre-existing cardiac conditions, especially heart failure or a history of arrhythmia, lower the threshold for dangerous rhythms.
- Taking multiple QT-prolonging drugs. Combining two medications that each stretch the QT interval, even modestly, can push the total effect into a dangerous range.
Drug Interactions That Raise Levels
Some medications don’t directly prolong QTc themselves but increase the blood concentration of your antipsychotic by interfering with liver enzymes that break it down. The result is the same as taking a higher dose: more drug in your system means more potassium channel blockade and a longer QT interval.
Quetiapine is metabolized almost entirely through a liver enzyme called CYP3A4. Drugs that compete for or inhibit that enzyme, including the antidepressant fluvoxamine, certain calcium channel blockers like amlodipine, and the cholesterol drug lovastatin, can raise quetiapine levels significantly. Two published case reports tied CYP3A4 interactions with quetiapine directly to torsades de pointes.
Risperidone is processed through a different enzyme, CYP2D6. The antidepressants fluoxetine and paroxetine are potent inhibitors of CYP2D6, so taking either alongside risperidone can substantially increase risperidone’s blood concentration. This kind of interaction is especially common in older adults taking multiple medications, where the chance of an overlooked enzyme conflict is highest.
Key QTc Thresholds and What They Mean
A normal QTc is generally below 450 ms in men and below 470 ms in women. Risk is categorized into tiers based on how far the interval stretches:
- Below 450 ms (men) or 470 ms (women): Low risk. Routine monitoring is sufficient.
- 450 to 499 ms (men) or 470 to 499 ms (women): Intermediate risk. Electrolytes should be checked and corrected, and the medication list reviewed for additive QT effects.
- Above 500 ms: High risk. This is the threshold most strongly associated with torsades de pointes. A dose reduction or switch to a lower-risk antipsychotic is typically warranted, along with a cardiology referral.
- Increase of more than 60 ms from baseline: Also considered high risk, regardless of the absolute number.
That said, torsades de pointes doesn’t happen exclusively above 500 ms. In one case series, about 21% of torsades episodes occurred at QTc values below 500 ms, reinforcing that the absolute number is a guide rather than a guarantee.
Practical Monitoring
A baseline ECG before starting an antipsychotic gives you a reference point, and annual ECGs help catch gradual changes. If potassium or magnesium levels are low, correcting them to a potassium level around 4.0 and a magnesium level around 2.0 can meaningfully reduce QTc risk. Using one antipsychotic rather than stacking two is strongly preferred, and if a second psychiatric medication is needed, choosing one that doesn’t also prolong QTc helps keep the cumulative effect manageable.
If QTc does climb above 500 ms, the first step is usually ruling out reversible causes like electrolyte problems or a new interacting medication before discontinuing the antipsychotic. Abruptly stopping psychiatric medication carries its own serious risks, so switching to a lower-risk alternative like lurasidone or aripiprazole is generally preferable to stopping treatment altogether.